Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Food Scene
Community Directory
Community Service
Restaurant Guide
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Horizons
Outdoor Guide
Progress
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2022 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
March 10, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
February 27, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
February 14, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
January 09, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
January 03, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
December 21, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 08, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 02, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
October 27, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
October 20, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
October 13, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
September 12, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
September 01, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 08, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
August 04, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
July 25, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
July 18, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
June 17, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Stock Trading Halted Today
June 17, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
May 04, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 03, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
May 02, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
April 21, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
April 18, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
March 22, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
February 16, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
February 14, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
February 11, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
January 10, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
STOK
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.